Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate

Cancer Journal

Volumn 10, Issue 6, 2004, Pages 349-356

  Perez, Carlos A ^a,b   Michalski, Jeff ^a,b   Mansur, David ^a,b   Lockett, Mary Ann ^a,b  

^a Washington University Medical Center ^*  (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma of the prostate; Elapsed treatment time; Radiation therapy

Indexed keywords

ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; THERAPY DELAY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BLOOD; CARCINOMA; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION; RADIOGRAPHY; TIME;

PROSTATE SPECIFIC ANTIGEN;

AGED; CARCINOMA; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TIME FACTORS;

EID: 15744376494     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200411000-00004     Document Type: Article

References (36)

1. Perez CA, Brady LW, Roti Roti JL. Overview. In: Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology (3rd ed). Philadelphia: Lippincott-Raven Publishers, 1998:1-78.
2. Lai PP, Perez CA, Shapiro SJ et al. Carcinoma of the prostate stage B and C: lack of influencer of duration of radiotherapy on tumor control and treatment morbidity. Int J Radiat Oncol Biol Phys 1990;19:561-568.
3. Lai PP, Pilepich MV, Krall JM et al. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radial Oncol Biol Phys 1991;21: 925-933.
4. Forman JD, Zinreich E, Lee DJ et al. Improving the therapeutic ratio of external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1985;11:2073-2080.
5. Parsons JT, Thar TL, Bova RJ et al. An evaluation of split-course irradiation for pelvic malignancies. Int J Radiat Oncol Biol Phys 1980;6:175-181.
6. Amdur RJ, Parsons JT, Fitzgerald LT et al. The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. Int J Radiat Oncol Biol Phys 1990;19:1377-1382.
7. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43: 1095-1101.
8. Duchese GM, Peters LJ. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:747-748.
9. Kal HB, Van Gellekom MP. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;57:1116-1121.
10. Wang JZ, Li A, Yu CX et al. The low α/β ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys 2003;57:1101-1108.
11. Perez CA, Michalski JM, Purdy JA et al. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 2000;47:629-637.
12. Perez CA. Prostate. In: Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology (3rd ed). Philadelphia: Lippincott-Raven, 1998;1583-1694.
13. International Commission on Radiation Units and Measurements. Report No. 50. Prescribing, recording, and reporting photon beam therapy. Washington, DC: ICRU, 1993.
14. American Society of Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
15. Cutler SJ, Ederer F. Maximum ulilization of the life table method in analyzing survival. J Chron Dis 1958;8:699-713.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 50:163-170.
17. Maciejewski B, Withers HR, Taylor JMG et al. Dose fractions and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 1989;16:831-843.
18. Taylor JMG, Withers HR, Mendenhall WM. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 1990;17:95-102.
19. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146.
20. Withers HR, Peters LJ, Taylor JM et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 1995;33: 549-562.
21. Fyles A, Keane TJ, Barton M et al. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25: 273-279.
22. Lanciano RM, Pajak TF, Martz K et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a Patterns of Care Study. Int J Radiat Oncol Biol Phys 1993;25:391-406.
23. Perez CA, Grigsby PW, CastroVita H et al. Carcinoma of the uterine cervix: I. Impact of prolongation of treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275-1288.
24. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984;10:401-409.
25. Perez CA, Lee HK, Georgiou A et al. Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;26: 567-580.
26. Hanks GE, Hanlon AL, Pinover WH et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 1999;5:152-158.
27. Corn BW, Hanks GE, Schultheiss TE et al. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 1995;32:325-330.
28. Hanks GE, Hanlon AL, Pinover WH et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46:823-832.
29. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-459.
30. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-3911.
31. Fiveash JF, Hanks GE, Roach M III et al. 3D conformal radiation therapy for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 2000;47:335-342.
32. Pinover WH, Hanlon AL, Horwitz EM, Hanks GE. Defining the appropriate dose for prostate cancer patients with PSA < 10 ng/mL. Int J Radiat Oncol Biol Phys 2000;47:649-654.
33. Kupelian PA, Buchsbaum JC, Reddy CA et al. Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason ≤ 6, and pretreatment prostate-specific antigen ≤ 10). Int J Radiat Oncol Biol Phys 2001;50:621-625.
34. Leibel SA, Fuks Z, Zelefsky MJ et al. Intensity-modulated radiotherapy. Cancer J 2002;8:164-176.
35. Michalski JM, Winter K, Purdy JA et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 2003;56:192-198.
36. Michalski JM, Winter K, Purdy JA et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004;58:735-742.